Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06578195 · ClinicalTrials.gov registry record

ASSESS ALL ALS Study

A clinical trial of Amyotrophic Lateral Sclerosis, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

Recruiting
Registry status
2,000
Enrollment target
20
Study locations

NCT06578195 is a study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 2,000 participants, above the 878-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (128% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06578195, a study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.

RECRUITING
Registry status
2,000 participants
Enrollment target
20
Study locations

Study Summary

The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.

Study Locations (20)

California

  • University of California, Irvine - Irvine
  • University of California San Diego - La Jolla
  • University of California, San Francisco - San Francisco

Maryland

  • John Hopkins University - Baltimore
  • Nih/Ninds - Bethseda

Michigan

  • University of Michigan - Ann Arbor
  • Henry Ford Health - Detroit

Alabama

  • University of Alabama Birmingham - Birmingham

Arizona

  • Barrow Neurological Institute - Phoenix

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Connecticut

  • Hospital For Special Care - New Britain

District of Columbia

  • Georgetown University - Washington D.C.

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2024-07-25
Est. Completion 2029-07-25

What the Registry Record Tells You About NCT06578195

The ClinicalTrials.gov registry entry for NCT06578195 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 878-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (128% higher). The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT06578195 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Maryland, Michigan.

Frequently Asked Questions

What is clinical trial NCT06578195 about?

NCT06578195 is a clinical study titled "ASSESS ALL ALS Study". The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Healt...

What is the current status of trial NCT06578195?

This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-07-25. Estimated completion is 2029-07-25.

What conditions does trial NCT06578195 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.

Who is sponsoring clinical trial NCT06578195?

This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06578195 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.